

INTERLEUKIN GENETICS INC
Form 4
August 03, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
PYXIS INNOVATIONS INC

2. Issuer Name and Ticker or Trading Symbol
INTERLEUKIN GENETICS INC
[ILIU]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
7575 FULTON STREET EAST
(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
07/29/2016

____ Director
____ Officer (give title below)
 10% Owner
____ Other (specify below)

ADA, MI 49355-0001

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
			Code	V	Amount	(D)	
Common Stock	07/29/2016		P		5,030,181	A	\$ 0.0994
					42,595,659	D	(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount
Common Stock Warrant (right to buy)	\$ 0.0994	07/29/2016		P	5,030,181	07/29/2016	07/29/2023	Common Stock	5,030,181

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
PYXIS INNOVATIONS INC 7575 FULTON STREET EAST ADA, MI 49355-0001		X		
Alticor Global Holdings Inc. 7575 FULTON STREET EAST ADA, MI 49355-0001		X		
SOLSTICE HOLDINGS INC 7575 FULTON STREET EAST ADA, MI 49355-0001		X		
ALTICOR INC 7575 FULTON STREET EAST ADA, MI 49355-0001		X		

Signatures

/s/ Rainey S. Repins, Assistant Secretary	08/03/2016
_____ **Signature of Reporting Person	Date
ALTICOR GLOBAL HOLDINGS INC., /s/ Cheon Kim, Assistant Secretary	08/03/2016
_____ **Signature of Reporting Person	Date
SOLSTICE HOLDINGS INC., /s/ Cheon Kim, Assistant Secretary	08/03/2016
_____ **Signature of Reporting Person	Date
ALTICOR INC., /s/ Cheon Kim, Assistant Secretary	08/03/2016
_____ **Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The reported securities are owned directly by Pyxis Innovations Inc., which is a wholly owned subsidiary of Alticor Inc., which is a
(1) wholly owned subsidiary of Solstice Holdings Inc., which is a wholly owned subsidiary of Alticor Global Holdings Inc. Alticor Inc., Solstice Holdings Inc. and Alticor Global Holdings Inc. are indirect beneficial owners of the reported securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.